Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

399
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
399
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

707
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
707
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

1.4K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.4K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

2.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

449
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
449

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vascular changes in hypertrophic cardiomyopathy.

Cardiovascular research·2026
Same author

RBM20 variants disrupt Ca<sup>2+</sup> handling and metabolism in dilated and non-compaction cardiomyopathy stem cell models.

Signal transduction and targeted therapy·2026
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Nature cardiovascular research·2026
Same author

Peroxisomal catalase and plasmalogen biosynthesis protect from oxidative stress in Barth syndrome cardiomyopathy.

Basic research in cardiology·2026
Same author

Desmoglein-2 deficiency drives mitochondrial morphological remodeling in cardiomyocytes.

American journal of physiology. Heart and circulatory physiology·2026

Related Experiment Video

Updated: Jan 14, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.6K

Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.

Anton Xu1, David Weissman1, Katharina J Ermer1

  • 1Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).

Circulation
|October 20, 2025
PubMed
Summary

Hypertrophic cardiomyopathy (HCM) involves impaired creatine kinase (CK) function due to oxidative stress from hypercontractility. Targeting hypercontractility and oxidative stress may restore energy balance and reduce arrhythmia risk in HCM.

Keywords:
arrhythmiascreatine kinasehypercontractilityhypertrophic cardiomyopathymyocardial energeticsoxidative stress

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

7.0K

Related Experiment Videos

Last Updated: Jan 14, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.6K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

7.0K

Area of Science:

  • Cardiology
  • Biochemistry
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common inherited heart disorder characterized by left ventricular hypertrophy and hypercontractility, leading to an energy deficit.
  • Creatine kinase (CK) is crucial for cardiac energy homeostasis, but its role in HCM pathophysiology is not fully understood.
  • This study explores how mitochondrial stress and increased hydrogen peroxide (H₂O₂) production in HCM disrupt CK function.

Purpose of the Study:

  • To investigate the impact of hypercontractility-driven mitochondrial stress on creatine kinase (CK) function in hypertrophic cardiomyopathy (HCM).
  • To elucidate the mechanisms linking mitochondrial reactive oxygen species (ROS) and CK dysfunction in HCM.
  • To evaluate potential therapeutic strategies targeting hypercontractility and oxidative stress in HCM.

Main Methods:

  • Analyzed myocardial tissue from HCM patients and controls for CK isoforms using various biochemical and proteomic techniques.
  • Utilized mouse models, including CK knockout and HCM-associated variants, to study hypercontractility, mitochondrial ROS, and CK function.
  • Investigated the effects of pharmacological agents like Ca²⁺ sensitizers, CK inhibitors, and myosin inhibitors on cardiomyocyte function and oxidative stress.

Main Results:

  • HCM myocardium showed reduced CK levels and activity, primarily due to oxidative damage.
  • In mouse models, hypercontractility induced by EMD-57033 increased mitochondrial H₂O₂, leading to CK inactivation and arrhythmias.
  • Mice with enhanced H₂O₂ scavenging and treatment with myosin inhibitor MYK-581 demonstrated protection against oxidative stress, arrhythmias, and preserved CK function.

Conclusions:

  • Established a mechanistic link between hypercontractility, mitochondrial ROS, and CK dysfunction in HCM, creating a cycle of energetic impairment.
  • Myosin inhibition emerges as a promising therapeutic strategy to address hypercontractility and oxidative stress, thereby restoring cardiac energy balance and reducing arrhythmia risk in HCM.